Ultrasound training simulator developer MedSim of Kfar-Sava, Israel, and contrast agent firm Sonus Pharmaceuticals of Bothell, WA, have agreed to jointly develop a training program that will help physicians learn to use ultrasound contrast more
Ultrasound training simulator developer MedSim of Kfar-Sava, Israel, and contrast agent firm Sonus Pharmaceuticals of Bothell, WA, have agreed to jointly develop a training program that will help physicians learn to use ultrasound contrast more effectively. The two companies are planning to develop a contrast module that will run on MedSim's UltraSim ultrasound training simulator (SCAN Special Report 4/97).
UltraSim enables users to conduct virtual ultrasound exams by scanning a mannequin and accessing ultrasound data stored on CD-ROM that correspond to the area being examined. Sonus hopes an UltraSim contrast module will help the company train large numbers of physicians in the use of its EchoGen contrast agent for echocardiography. The companies plan to conduct a feasibility study on the module at a major U.S. ultrasound teaching institution.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.